B+
Bull case
25%
Probability
Target price
$10.00
+55.8% vs current
RLMD
Relmada TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$7.50
+16.8% vs current
B-
Bear case
30%
Probability
Target price
$4.50
-29.9% vs current
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+61.5
Score
AI commentary
Current sentiment is cautiously constructive but not strong. The March 2026 10-K and related 8-K corporate update show a company that has pivoted away from REL-1017, is centered on NDV-01 and sepranolone, and has near-term liquidity for planned 2026 milestones, yet forward visibility is still mainly management-timeline based rather than data-driven [#10-K-2026-03-19] [#8-K-2026-03-20].
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventNDV-01 U.S. IND clearance / Phase 3 start target in mid-2026High impact
Relmada said in its 2025 Form 10-K that it expects NDV-01 U.S. IND clearance and Phase 3 initiation for high-risk BCG-unresponsive NMIBC in mid-2026; hitting that timeline would be the first material execution proof for the post-REL-1017 strategy shift [#10-K-2026-03-19].
2026-06-30eventSepranolone Phase 2b study initiation target in PWSHigh impact
The 2025 Form 10-K says sepranolone is Phase 2b-ready and that Relmada expects to initiate a Phase 2b study in Prader-Willi syndrome in mid-2026; launch of that study would broaden the pipeline but remains an execution milestone rather than clinical proof [#10-K-2026-03-19].
2027-03-19catalystRunway supports near-term milestones but likely not a full multi-program buildout without more capitalHigh impact
Relmada reported about $93.0 million of cash, cash equivalents, and short-term investments at December 31, 2025, and stated existing resources should fund operations for at least 12 months from issuance of the audited financials, while noting later trial scope will affect the timing of additional financing or partnering; that lowers immediate distress risk but leaves medium-term dilution or deal dependence in view [#10-K-2026-03-19].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology